Prof Andrew Wei speaks to ecancer at the 2019 ASH meeting in Orlando about results from the QUAZAR AML-001 trial.
The trial aim was to investigate if maintenance therapy with CC-486 (an oral formulation of azacitidine) could lead to improvements in overall survival of acute myeloid leukaemia (AML) patients in first remission.
Prof Wei reports improvements in overall survival, relapse-free survival and benefits across different prognostic subsets of AML.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.